Journal article
Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand
T Blakely, G Kvizhinadze, T Karvonen, AL Pearson, M Smith, N Wilson
Vaccine | ELSEVIER SCI LTD | Published : 2014
Abstract
Background: As with many high-income countries, vaccination coverage against human papilloma virus (HPV) infection is not high in New Zealand (NZ) at 47% in school-aged girls for three doses. We estimate the health gains, net-cost and cost-effectiveness of the currently implemented HPV national vaccination programme of vaccination dispersed across schools and primary care, and two alternatives: school-based only (assumed coverage as per Australia: 73%), and mandatory school-based vaccination but with opt-out permitted (coverage 93%). We also generate estimates by social group (sex, ethnic and deprivation group). Methods: A Markov macro-simulation model was developed for 12-year-old girls and..
View full abstractGrants
Awarded by Health Research Council of New Zealand
Funding Acknowledgements
TB, TK and NW conceived of the study, while TB led the study design and interpretation, and led the write up. GK contributed to model specification, and undertook all analyses, with quality control checks provided by TB and AP. TK, AP and NW contributed to the model specification, undertook literature searches and data collation on specific tasks, and assisted drafting of the paper. MS contributed to interpretation and write up. Funding: The BODE<SUP>3</SUP> Programme receives funding support from the Health Research Council of New Zealand (10/248). Conflicts of interest: The authors have no conflicts of interest.